BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Min Kim, James Paik, Pegah Golabi, Thomas Jeffers, Alita Mishra, Zobair M. Younossi. Resource Utilization and Outcomes of Medicare Recipients With Chronic Hepatitis B in the United StatesJournal of Clinical Gastroenterology 2019; 53(8): e341 doi: 10.1097/MCG.0000000000001110
2
M. von Wulffen, P. J. Clark, G. A. Macdonald, A. S. Raj, B. J. Kendall, E. E. Powell, M. P. Jones, G. Holtmann. Liver-related mortality in countries of the developed world: an ecological study approach to explain the variabilityAlimentary Pharmacology & Therapeutics 2016; 44(1): 68 doi: 10.1111/apt.13657
3
Su-Su Zhang, Jin-Xia Liu, Jing Zhu, Ming-Bing Xiao, Cui-Hua Lu, Run-Zhou Ni, Li-Shuai Qu. Effects of TACE and preventive antiviral therapy on HBV reactivation and subsequent hepatitis in hepatocellular carcinoma: a meta-analysisJapanese Journal of Clinical Oncology 2019; 49(7): 646 doi: 10.1093/jjco/hyz046
4
Sandra Coenen, Suzanne van Meer, Jan M. Vrolijk, Clemens Richter, Karel J. van Erpecum, Marijke C. Mostert, Irene K. Veldhuijzen, Jurriën G. P. Reijnders, Hanneke van Soest, Kees Dirksen, Joost P. H. Drenth, René P. M. Koene, Maaike Bosschart, Pieter Friederich, Martijn J. ter Borg, Rick H. P. J. Daemen, Joop E. Arends, Marc A. M. T. Verhagen, Christine Schout, B. W. Marcel Spanier. Clinical impact of five large-scale screening projects for chronic hepatitis B in Chinese migrants in the NetherlandsLiver International 2016; 36(10): 1425 doi: 10.1111/liv.13125
5
Ioannis Varbobitis, George V. Papatheodoridis. The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapyClinical and Molecular Hepatology 2016; 22(3): 319 doi: 10.3350/cmh.2016.0045